Compare Amylx Pharmaceuticals Inc (AMLX) vs Expedia Group Inc (EXPE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Expedia Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Expedia Group Inc trades at $270.82 (market cap $32.51B). The key difference: Expedia Group Inc is far larger — about 16.4× Amylx Pharmaceuticals Inc's market cap, and Expedia Group Inc pays a 0.65% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EXPE | |
|---|---|---|
Market Cap | $1.98B | $32.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $301.31 |
52-Week Low | $7.64 | $178.06 |
Enterprise Value | $1.70B | $31.42B |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Expedia Group (EXPE) trades at $270.83, up 1.14% with a bullish technical signal and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.96 exceeding expectations by 39%. Revenue growth has accelerated from $11.7B in 2022 to $14.7B in 2025, while net income margins improved to 9.81%. Recent developments include the CarTrawler acquisition and AI initiatives, positioning the company for continued travel sector leadership.
Outlook remains positive with analyst consensus target of $285.44 offering 5.4% upside. Key opportunities include travel demand recovery and operational efficiency gains, while risks involve macroeconomic sensitivity and competitive pressures. The stock presents a balanced risk-reward profile with strong institutional support and improving financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
